| Profound Medical Annual General and Special Meeting of Shareholders Voting Results |
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders that was held today (the “Meeting”). A total of 20,587,011 common shares, representing 68.5% of the common shares outstanding, were represented in person and by proxy at the Meeting. |
globenewswire.com |
2025-05-14 20:45:00 |
Czytaj oryginał (ang.) |
| Profound Medical Corporation (PROF) Q1 2025 Earnings Conference Call Transcript |
Profound Medical Corporation (NASDAQ:PROF ) Q1 2025 - Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Stephen Kilmer - Head IR Rashed Dewan - CFO Dr. Mathieu Burtnyk - COO Tom Tamberrino - Chief Commercial Officer Arun Menawat - CEO Conference Call Participants Ben Haynor - Lake Street Capital Markets John McAuley - Stifel Michael Freeman - Raymond James Scott McAuley - Paradigm Capital Operator Good day, and thank you for standing by. Welcome to the Profound Medical First Quarter 2025 Financial Results Conference Call. |
seekingalpha.com |
2025-05-09 11:17:42 |
Czytaj oryginał (ang.) |
| Profound Medical (PROF) Reports Q1 Loss, Misses Revenue Estimates |
Profound Medical (PROF) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.26 per share a year ago. |
zacks.com |
2025-05-08 23:20:37 |
Czytaj oryginał (ang.) |
| Strength Seen in Profound Medical (PROF): Can Its 8.3% Jump Turn into More Strength? |
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2025-05-05 15:01:09 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF |
NEW YORK CITY, NY / ACCESS Newswire / May 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ:PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-03 14:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF |
Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ:PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-01 14:15:00 |
Czytaj oryginał (ang.) |
| Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference |
TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company's business at the 2025 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, May 6, 2025 at 1:30 p.m. Eastern Time at the Metro Toronto Convention Centre. |
globenewswire.com |
2025-04-30 20:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF |
NEW YORK, NY / ACCESS Newswire / April 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ:PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-04-30 16:25:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF |
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. (“Profound” or the “Company”) (NASDAQ: PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. |
globenewswire.com |
2025-04-29 17:15:00 |
Czytaj oryginał (ang.) |
| Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy |
– First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate cancer – – TULSA had no blood loss and no overnight stay, along with reduced post-procedure pain, and more rapid recovery to baseline activities and overall health – TORONTO, April 29, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, is pleased to announce initial perioperative data from the Level 1 post-market CAPTAIN trial comparing the safety and efficacy of the TULSA procedure with radical prostatectomy (“RP”) in men with organ-confined, intermediate-risk, Gleason Score 7 (Grade Group 2 and 3) prostate cancer. The positive perioperative results were presented yesterday by Xiaosong Meng, M.D. |
globenewswire.com |
2025-04-29 11:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF |
NEW YORK , April 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ: PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-04-28 22:09:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF |
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. (“Profound” or the “Company”) (NASDAQ: PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. |
globenewswire.com |
2025-04-25 19:31:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF |
NEW YORK CITY, NY / ACCESS Newswire / April 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ:PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-04-24 12:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF |
NEW YORK, NY / ACCESS Newswire / April 23, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ:PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-04-23 14:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF |
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. (“Profound” or the “Company”) (NASDAQ: PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. |
globenewswire.com |
2025-04-21 19:38:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF |
NEW YORK, NY / ACCESS Newswire / April 20, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ:PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-04-20 04:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF |
NEW YORK, NY / ACCESS Newswire / April 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ:PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-04-18 17:15:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF |
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. (“Profound” or the “Company”) (NASDAQ: PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. |
globenewswire.com |
2025-04-17 18:10:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF |
NEW YORK CITY, NY / ACCESS Newswire / April 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ:PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-04-16 17:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF |
NEW YORK CITY, NY / ACCESS Newswire / April 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ:PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-04-15 19:00:00 |
Czytaj oryginał (ang.) |
| Will Profound Medical (PROF) Report Negative Earnings Next Week? What You Should Know |
Profound Medical (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-27 13:06:30 |
Czytaj oryginał (ang.) |
| Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow |
TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025. |
globenewswire.com |
2025-02-13 19:00:00 |
Czytaj oryginał (ang.) |
| K18 EXPANDS REACH WITH LAUNCH AT COSMO PROF, FURTHER EMPOWERING PROFESSIONAL STYLISTS |
The biotech haircare brand strengthens its commitment to the stylist community with innovative products and education SAN FRANCISCO , Feb. 6, 2025 /PRNewswire/ -- K18 Biomimetic Hairscience, the cutting-edge biotech haircare brand, is proud to announce its upcoming launch at Cosmo Prof today. This marks the brand's continued expansion to support professional stylists, with its high-performance products, accessible education, and revolutionary biotechnology now available through Cosmo Prof's expansive network as the largest distributor of professional branded beauty products to the salon community in North America. |
prnewswire.com |
2025-02-06 11:00:00 |
Czytaj oryginał (ang.) |
| Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues |
– Fourth quarter revenue growth estimated at 105% to 110% year-over-year – – Company to start reporting in accordance with U.S. GAAP and filing with the SEC on U.S. domestic forms – – Profound reminds investors that it is scheduled to present at JPM 2025 on January 16 th at 11:15 a.m. PT – TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced preliminary unaudited revenues for the fourth quarter and full year 2024. |
globenewswire.com |
2025-01-08 09:30:00 |
Czytaj oryginał (ang.) |
| Does Profound Medical (PROF) Have the Potential to Rally 100.13% as Wall Street Analysts Expect? |
The average of price targets set by Wall Street analysts indicates a potential upside of 100.1% in Profound Medical (PROF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-01-07 13:06:11 |
Czytaj oryginał (ang.) |
| Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company's business at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 11:15 a.m. Pacific Time in San Francisco, CA. |
globenewswire.com |
2025-01-06 10:15:00 |
Czytaj oryginał (ang.) |
| Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares |
TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of common shares (the “Common Shares”) at a public offering price of US$7.50 per Common Share. The underwriters elected to exercise the over-allotment option in full, resulting in an aggregate of 5,366,705 Common Shares being issued today for aggregate gross proceeds, before deducting the underwriting discounts and commissions and other offering expenses payable by Profound, of approximately US$40.25 million. |
globenewswire.com |
2024-12-10 11:55:00 |
Czytaj oryginał (ang.) |
| Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares |
BASE SHELF PROSPECTUS IS ACCESSIBLE, AND FINAL PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR |
globenewswire.com |
2024-12-06 11:04:00 |
Czytaj oryginał (ang.) |
| Profound Medical Announces Proposed Public Offering of Common Shares |
BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR |
globenewswire.com |
2024-12-05 18:48:00 |
Czytaj oryginał (ang.) |
| Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy |
– Combines Profound's TULSA-PRO ® and Siemens Healthineers' Magnetom Free.Max – – Supports the Modern Treatment Pathway that allows for more accurate and precise diagnosis, treatment, and follow-up – – Aligns well with CMS 2025 Final Rule establishing Urology APC Level 7 reimbursement for TULSA procedure at all 3 sites of service – TORONTO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that it has entered into a definitive co-sales and co-marketing agreement with Siemens Healthineers, a global leader in medical technology, pursuant to which the companies will commercialize a new MRI-guided prostate therapy solution which combines Profound's TULSA-PRO® system and consumables with Siemens Healthineers' Magnetom Free.Max magnetic resonance (“MR”) scanner.1 The Transurethral Ultrasound Ablation (“TULSA”) procedure, performed using Profound's TULSA-PRO® system, employs real-time MR guidance for precision to preserve prostate disease patients' urinary continence and sexual function, while killing the targeted prostate tissue via a precise sound absorption technology that gently heats it to kill temperature (55-57°C). TULSA-PRO® enables surgeons to ablate whole- or partial-gland prostate tissue in patients with low-, intermediate, or high-risk prostate cancer; with benign prostatic hyperplasia (“BPH”); as well as those prostate cancer patients on active surveillance seeking treatment of their cancer and relief from their symptoms of BPH. |
globenewswire.com |
2024-12-02 09:30:00 |
Czytaj oryginał (ang.) |
| Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant' |
TULSA procedure's unrivaled flexibility, real-world efficacy and ongoing CAPTAIN post-market study to be featured in the scientific programs at the upcoming RSNA and SUO meetings TULSA procedure's unrivaled flexibility, real-world efficacy and ongoing CAPTAIN post-market study to be featured in the scientific programs at the upcoming RSNA and SUO meetings |
globenewswire.com |
2024-11-26 09:45:00 |
Czytaj oryginał (ang.) |
| Profound Medical Corporation (PROF) Q3 2024 Earnings Call Transcript |
Profound Medical Corporation (NASDAQ:PROF ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Stephen Kilmer - IR Arun Menawat - CEO Rashed Dewan - CFO Mathieu Burtnyk - COO Conference Call Participants Benjamin Haynor - Lake Street Capital Markets John Baugh - Stifel Michael Freeman - Raymond James Scott McAuley - Paradigm Capital Operator Good day and thank you for standing by. Welcome to the Profound Medical Third Quarter 2024 Financial Results Conference Call. |
seekingalpha.com |
2024-11-10 10:50:30 |
Czytaj oryginał (ang.) |
| Profound Medical (PROF) Reports Q3 Loss, Lags Revenue Estimates |
Profound Medical (PROF) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.26 per share a year ago. |
zacks.com |
2024-11-07 21:26:09 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict a 106.45% Upside in Profound Medical (PROF): Here's What You Should Know |
The consensus price target hints at a 106.5% upside potential for Profound Medical (PROF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-11-06 12:55:25 |
Czytaj oryginał (ang.) |
| Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025 |
– TULSA to stand above all other covered prostate disease treatment modalities at Urology Level 7 reimbursement – – First-time CPT® code reimbursement for TULSA to be effective January 1, 2025 – TORONTO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that U.S. Centers for Medicare and Medicaid Services (“CMS”) has released its final rule (the “Final Rule”) establishing, for the first time, a Category 1 CPT® code for the Transurethral Ultrasound Ablation (“TULSA”) procedure, effective January 1, 2025. According to the Final Rule, TULSA will have three codes to cover how therapy is delivered depending on if there are one or two physicians involved in the procedure: CPT 51721 TULSA Device Management and CPT 55881 TULSA Treatment, when two physicians are involved in the procedure, and CPT 55882 TULSA Complete Procedure, when performed by a single physician. |
globenewswire.com |
2024-11-04 08:55:00 |
Czytaj oryginał (ang.) |
| Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow |
TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2024 financial results after market close on Thursday, November 7, 2024. |
globenewswire.com |
2024-10-17 20:30:00 |
Czytaj oryginał (ang.) |
| Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer |
– Mr. Tamberrino and Profound's CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – |
globenewswire.com |
2024-10-16 20:15:00 |
Czytaj oryginał (ang.) |
| Profound Medical (PROF) Moves 5.1% Higher: Will This Strength Last? |
Profound Medical (PROF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2024-09-27 10:31:11 |
Czytaj oryginał (ang.) |
| Profound Medical to Participate in Lake Street's Best Ideas Growth Conference |
TORONTO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth “Big8” Conference on September 12, 2024 in New York City. |
globenewswire.com |
2024-09-04 20:30:00 |
Czytaj oryginał (ang.) |
| Profound Medical Corporation (PROF) Q2 2024 Earnings Call Transcript |
Profound Medical Corporation (NASDAQ:PROF ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Stephen Kilmer - IR Arun Menawat - CEO Rashed Dewan - CFO Mathieu Burtnyk - COO Conference Call Participants Rick Wise - Stifel Ben Haynor - Lake Street Capital Markets Rahul Sarugaser - Raymond James Michael Sarcone - Jefferies Scott McAuley - Paradigm Capital Brian Gagno - Gagnon Securities Operator Welcome to the Profound Medical Second Quarter 2024 Financial Results conference call. [Operator Instructions]. |
seekingalpha.com |
2024-08-09 03:11:07 |
Czytaj oryginał (ang.) |
| Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates |
Profound Medical (PROF) came out with a quarterly loss of $0.28 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.35 per share a year ago. |
zacks.com |
2024-08-08 22:31:05 |
Czytaj oryginał (ang.) |
| Profound Medical (PROF) Expected to Beat Earnings Estimates: Can the Stock Move Higher? |
Profound Medical (PROF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-08-01 15:06:07 |
Czytaj oryginał (ang.) |
| Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow |
TORONTO, July 18, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2024 financial results after market close on Thursday, August 8, 2024. |
globenewswire.com |
2024-07-18 20:30:00 |
Czytaj oryginał (ang.) |
| Profound Medical (PROF) Surges 6.0%: Is This an Indication of Further Gains? |
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2024-07-17 13:30:43 |
Czytaj oryginał (ang.) |
| Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases |
TORONTO, July 11, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that U.S. Centers for Medicare and Medicaid Services (CMS) has issued its proposed rules establishing, for the first time, a Category 1 CPT code for the Transurethral Ultrasound Ablation (“TULSA”) procedure, effective January 1, 2025. |
globenewswire.com |
2024-07-11 11:00:00 |
Czytaj oryginał (ang.) |
| Profound Medical (PROF) Adds AI to Prostate Cancer Treatment |
Profound Medical's (PROF) Contouring Assistant integrates AI into prostate cancer procedures, thereby streamlining the treatment planning process and enhancing both efficiency and precision. |
zacks.com |
2024-05-16 14:21:15 |
Czytaj oryginał (ang.) |